Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>
Idioma: En

Alnylam Announces Unaudited Fourth Quarter 2018 Global Revenues for ONPATTRO® (patisiran) and Provides Additional Commercial Updates

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today pre-announced its Unaudited Fourth Quarter 2018



This post first appeared on Global Banking And Finance Review Magazine – Fin, please read the originial post: here

Share the post

Alnylam Announces Unaudited Fourth Quarter 2018 Global Revenues for ONPATTRO® (patisiran) and Provides Additional Commercial Updates

×

Subscribe to Global Banking And Finance Review Magazine – Fin

Get updates delivered right to your inbox!

Thank you for your subscription

×